Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20937613 | 0.92 | USP2 (0.53) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL933177 | 0.92 | USP2 (0.53) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL742156 | 0.91 | USP2 (0.51) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL1779347 | 0.91 | USP2 (0.51) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL20937760 | 0.91 | USP2 (0.51) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL23257682 | 0.89 | USP2 (0.50) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL21341638 | 0.89 | USP2 (0.50) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL25935474 | 0.89 | USP2 (0.50) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL6868004 | 0.89 | CYP11B2 (0.54) | USP2SMN1; SMN2HPGDEPHX2CYP1A2 | |
| SCHEMBL31739286 | 0.88 | USP2 (0.46) | USP2SMN1; SMN2GPR119HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290338-A | Building block 6-azaspiro [2.5] octane synthesized by Sovilnesib as anticancer medicine for clinical research and its synthesizing process | 上海苏博医药科技有限公司 | 2024-07-05 | — | — | CN | claimed |
| EP-4126821-B1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | Rottapharm Biotech Srl (IT) | 2024-05-15 | — | — | EP | claimed |
| CN-122010910-A | Biazacycloalkane Menin-MLL protein inhibitor, pharmaceutical composition and application thereof | 赛诺哈勃药业（成都）有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250312504-A1 | VOLATILE COMPOSITION DISPENSER FOR COMPOSITIONS COMPRISING A META-(C1-C4 ALKOXY) SALICYLALDEHYDE | THE PROCTER & GAMBLE COMPANY | 2025-10-09 | — | — | US | disclosed |
| CN-120060868-A | Preparation method of 6-azaspiro [2.5] octane-6-carboxylic acid-1, 1-dimethylethyl ester | 南京药石科技股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120060868-A | Preparation method of 6-azaspiro [2.5] octane-6-carboxylic acid-1, 1-dimethylethyl ester | 南京药石科技股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120060868-A | Preparation method of 6-azaspiro [2.5] octane-6-carboxylic acid-1, 1-dimethylethyl ester | 南京药石科技股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-115843295-B | NAMPT modulators | 赛特凯恩蒂克公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2025054361-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-116322700-B | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-08-20 | — | — | CN | disclosed |
| CN-118515674-A | Amide compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-8039480-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2011-10-18 | — | — | US | disclosed |
| EP-2275421-A1 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | Rottapharm S.p.A. (IT) | 2011-01-19 | — | — | EP | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2010506-B1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-04 | — | — | EP | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| US-7632829-B2 | Diazepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2009-11-05 | — | — | US | disclosed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | USP2 763/4885SMN1; SMN2 3535/4885GPR119 4318/4885 |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | USP2 3243/4885SMN1; SMN2 4673/4885GPR119 1376/4885 |
| US-20070249589-A1 | Novel diazepan derivatives | CCR3, CCR1, CCR10 | USP2 3011/4885SMN1; SMN2 2573/4885GPR119 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.